Navigation Links
Hepatitis C Virus Market Will Expand Dramatically From $2 Billion in 2008 to Nearly $7.7 Billion in 2013
Date:6/22/2009

Roche and Schering-Plough Will Continue to be Prominent Players in the Market, According to a New Report from Decision Resources

WALTHAM, Mass., June 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the hepatitis C virus drug market will expand dramatically from $2 billion in 2008 to nearly $7.7 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. However, market growth thereafter will decrease to $3.4 billion in 2018 owing to a decline in the prevalence of the disease and the high efficacy of new treatment regimens.

The new Pharmacor report entitled Hepatitis C Virus finds that, through 2013, robust market growth will be driven by the launches of novel hepatitis C virus-specific agents and an increase in the size of the drug-treated population. Roche and Schering-Plough will continue to be prominent players and a number of other companies -- including Johnson & Johnson and Pfizer -- will also carve out a share in the market.

The report also finds that the competitive hepatitis C virus pipeline is characterized by its significant commercial potential which is well-recognized by drug developers. Several agents in late-stage development -- most notably protease inhibitors such as Vertex/Johnson & Johnson/Mitsubishi Tanabe's telaprevir and Schering-Plough's boceprevir as well as polymerase inhibitors such as Roche/Pharmasset's R-7128 and Pfizer's filibuvir -- will drive market growth.

"The standard of care will change significantly with the introduction of new classes of hepatitis C virus-specific antiviral agents, such as protease inhibitors and polymerase inhibitors," said Decision Resources Analyst Alexandra Makarova, M.D., Ph.D. "Compounds from these new classes will initially be added to the backbone of currently used agents, forming triple or quadruple treatment regimens that are expected to be more efficacious than the current standard of care."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                               Decision Resources, Inc.
    Christopher Comfort                              Elizabeth Marshall
    781-296-2597                                     781-296-2563
    ccomfort@dresources.com                          emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Good news for some hard-to-treat hepatitis C patients
2. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
3. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
4. NEJM study points to new era in hepatitis C treatment
5. Resource for Those Living with Hepatitis C Announces Website Redesign
6. AUDIO from Medialink, Bayer Healthcare and Onyx Pharmaceuticals: Facts About Hepatitis
7. New treatment option for patients with chronic hepatitis C
8. National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action
9. National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action
10. World Health Assembly Forced to Postpone Decision on Viral Hepatitis
11. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... Doctor ... announced it attended the January ECRM trade show to continue the marketing and distribution ... vitamin C supplement, known for providing 400 percent better absorption than traditional vitamin C ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Michael and ... Dana Farber Cancer Institute. For Betsy, the clinical trial has been life-saving as ... has not worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following ... Chocolate Biscuit” is the creation of published author, Marlyn Ivey, born in Lynn Haven, Florida ... went to school and at 19 years of age, he joined the Navy and got ...
(Date:1/20/2017)... ... ... is God’s Lighthouse”: a moving and colorful collection of prayers that reminds readers ... author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published works ... school and have many different titles,” Gaapf mentions about his different works. “I am ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Next week after ... be repealed by Congressional political games that circumvent health needs of over 30 million. ... capture the human anxieties and needs government public servants were suppose to prioritize. Interviews ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 According to ... for cryotherapy is set to witness a CAGR of 6.5% during ... America will continue to be the leading market for ... ... Suppliers are emphasizing on ensuring affordable and adequate supply of gas ...
(Date:1/19/2017)... Jan. 19, 2017 ViewRay, Inc. (Nasdaq: VRAY) announced ... institution supporting research in Germany , ... treatments at the University Clinic Heidelberg as part of ... MRIdian Linac program will be headed by Medical Director ... radiation oncology at the German Cancer Research Center (DKFZ), ...
(Date:1/19/2017)... BEACH, Florida , January 19, 2017 /PRNewswire/ ... incoming Trump administration appears serious about reducing the ... advancements and innovation in the medical drug industry, ... forge ahead with new clinical trials and development ... Pharma companies forging ahead with recent developments include:  ...
Breaking Medicine Technology: